Literature DB >> 15234132

Clinical risk factors for cytomegalovirus retinitis in patients with AIDS.

William G Hodge1, Jean-François Boivin, Stanley H Shapiro, Richard G Lalonde, Kirtida C Shah, Bradley D Murphy, Michel A Dionne, Aashish Goela.   

Abstract

PURPOSE: To determine the clinical risk factors for cytomegalovirus (CMV) retinitis in patients with AIDS.
DESIGN: A case-control study. PARTICIPANTS: The study included 120 patients in whom CMV retinitis had been diagnosed from 1990 through 1999 (cases) and 159 patients without CMV retinitis from the same period (controls). All individuals had AIDS and CD4 counts less than 50 cells/microl at the time of diagnosis of retinitis in the cases or on the corresponding date for the controls.
METHODS: Clinical risk factors were determined by history or physical examination. Confounders controlled for included CD4 count, hospital center, and a series of variables to control for confounding by drug treatment. Statistical analysis was performed by multivariate logistic regression. A systematic model-building strategy was developed from assumption testing to model building to model checking. MAIN VARIABLES MEASURED: Presence of visual symptoms, retinal microinfarctions (cotton-wool spots), history of opportunistic infections, and risk factors for human immunodeficiency virus acquisition were determined and compared in both groups.
RESULTS: The following clinical risk factors were significant predictors of CMV retinitis: flashing lights or floaters (odds ratio [OR], 11.42; 95% confidence interval [CI], 3.43 to 38.01), cotton-wool spots (OR, 2.90; 95% CI, 1.01 to 8.29), number of previous opportunistic infections (OR, 1.81; 95% CI, 1.24 to 2.64), previous nonocular CMV infection (OR, 82.99; 95% CI, 6.86 to 1004.58), previous Mycobacterium infection (OR, 3.41; 95% CI, 0.99 to 11.85), and homosexuality (OR, 2.83; 95% CI, 1.13 to 7.12).
CONCLUSIONS: Based on this study, clinical variables have been identified that elevate the risk of CMV retinitis. These findings may be useful to clinicians and health policy experts in developing rational guidelines for screening, examination frequency, and targeted prophylaxis for CMV retinitis in patients with AIDS.

Entities:  

Mesh:

Year:  2004        PMID: 15234132     DOI: 10.1016/j.ophtha.2004.03.001

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  5 in total

1.  Role of human cytomegalovirus genotype polymorphisms in AIDS patients with cytomegalovirus retinitis.

Authors:  Jens-Uwe Vogel; Jürgen Otte; Frank Koch; Hermann Gümbel; Hans Wilhelm Doerr; Jindrich Cinatl
Journal:  Med Microbiol Immunol       Date:  2012-06-06       Impact factor: 3.402

2.  Human immunodeficiency virus-related retinal microangiopathy and systemic cytomegalovirus disease association.

Authors:  Yuko Iwasaki; Narumichi Yamamoto; Tatsushi Kawaguchi; Noriko Ozaki; Makoto Tomita; Atsushi Ajisawa; Manabu Mochizuki; Kimio Murakami
Journal:  Jpn J Ophthalmol       Date:  2013-05-23       Impact factor: 2.447

3.  Risk factors for CMV retinitis among individuals with HIV and low CD4 count in northern Thailand: importance of access to healthcare.

Authors:  Prattana Leenasirimakul; Yingna Liu; Choeng Jirawison; Nitta Khienprasit; Siripim Kamphaengkham; Somsanguan Ausayakhun; Jenny Chen; Michael Yen; David Heiden; Gary N Holland; Todd P Margolis; Jeremy D Keenan
Journal:  Br J Ophthalmol       Date:  2016-06-13       Impact factor: 4.638

4.  Routine Eye Screening by an Ophthalmologist Is Clinically Useful for HIV-1-Infected Patients with CD4 Count Less than 200 /μL.

Authors:  Takeshi Nishijima; Shigeko Yashiro; Katsuji Teruya; Yoshimi Kikuchi; Naomichi Katai; Shinichi Oka; Hiroyuki Gatanaga
Journal:  PLoS One       Date:  2015-09-16       Impact factor: 3.240

5.  Diagnostic Utility of Ocular Symptoms and Vision for Cytomegalovirus Retinitis.

Authors:  Yingna Liu; Alexander S Chen; Siripim Kamphaengkham; Prattana Leenasirimakul; Choeng Jirawison; Somsanguan Ausayakhun; Todd P Margolis; Jeremy D Keenan
Journal:  PLoS One       Date:  2016-10-27       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.